Nanoscope Therapeutics has received Orphan Drug Designation in Saudi Arabia for MCO-010, enhancing its global regulatory leadership in vision restoration therapies.

Nanoscope Therapeutics has been awarded a U.S. patent for its innovative Multi-Characteristic Opsin platform, enhancing vision restoration technology and strategies.

Nanoscope Therapeutics will highlight its groundbreaking therapies for vision loss at the 2026 J.P. Morgan Healthcare Conference, showcasing significant regulatory and clinical advancements.

Nanoscope Therapeutics shines a spotlight on its innovative gene therapies during the Advanced Therapies USA 2025, aiming to restore vision for patients affected by retinal diseases.

Nanoscope Therapeutics is set to present significant findings at the upcoming American Academy of Ophthalmology Annual Meeting, focusing on vision-restoring therapies.

Nanoscope Therapeutics will showcase groundbreaking gene therapies aimed at restoring vision for blind patients at the 2025 BIO International Convention in Boston.

Nanoscope Therapeutics reveals groundbreaking findings on restoring vision in retinitis pigmentosa patients via innovative synthetic opsin therapy.

Nanoscope Therapeutics is set to present its groundbreaking vision restoration therapies at the H.C. Wainwright BioConnect Showcase, detailing new clinical advancements.

Nanoscope Therapeutics will showcase groundbreaking research at upcoming medical meetings, focusing on techniques for restoring vision in patients with severe sight loss.

Since its inception, the Cure Blindness Project has restored sight to over 1.6 million people worldwide, celebrating 30 years of impactful work.

The Bascom Palmer Eye Institute has secured a major grant to develop revolutionary whole-eye transplant techniques, with hopes of restoring vision.